Activation and Deactivation of a Broad-Spectrum Antiviral Drug by a Single Enzyme: Adenosine Deaminase Catalyzes Two Consecutive Deamination Reactions

AUTOR(ES)

Wu, Jim Zhen

FONTE

American Society for Microbiology

RESUMO

Ribavirin is an approved broad-spectrum antiviral drug. A liver-targeting prodrug of ribavirin, viramidine, is in clinical trial in an attempt to provide a better therapeutic index. The conversion of viramidine to ribavirin, and of ribavirin to an inactive metabolite through adenosine deaminase, is reported. Kinetic analysis indicates that adenosine deaminase is likely involved in activation of viramidine in vivo, and the process is highly pH sensitive. The differential activities of two consecutive deamination reactions are kinetically studied and interpreted based on adenosine deaminase structural information. A comprehensive understanding of the viramidine and ribavirin deamination mechanism should help in designing better nucleoside therapeutics in the future.

Documentos Relacionados

• Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin.
• Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin.
• Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.
• Broad-spectrum virus resistance in transgenic plants expressing pokeweed antiviral protein.
• In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug.